Overview

Ticagrelor Pharmacokinetics in NSTEMI

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Patients with myocardial infarction, which does not include all layers of the heart's muscle wall are common and they often receive pharmacological treatment with the platelet inhibiting drug ticagrelor. However, the drug uptake after an oral dose of 180mg ticagrelor has not been thoroughly studied in these patients. The present study will evaluate ticagrelor uptake and platelet aggregation after a 180 mg loading dose ticagrelor in these patients.
Details
Lead Sponsor:
Karolinska University Hospital
Collaborator:
AstraZeneca
Treatments:
Ticagrelor